Roche reported detrimental outcomes Monday from a pair of scientific trials investigating an antibody remedy for folks with early-stage Alzheimer’s illness — one other setback for the Swiss pharma large’s decades-long effort to develop medicines towards the memory-destroying illness.
The drug, known as gantenerumab, slowed the speed of cognitive and practical decline in comparison with a placebo by 8% and 6%, respectively, — not sufficient to satisfy the first aim of the 2 research of slightly below 2,000 sufferers with early-stage Alzheimer’s, Roche stated in a press launch.
window.statGlobal = window.statGlobal || { };
window.statGlobal.analytics = window.statGlobal.analytics || { };
window.statGlobal.analytics.fbq = function( eventName, parameters ) {
jQuery.ajax( {
url: ‘/wp-json/stat-analytics/v1/facebook-pixel’,
type: ‘POST’,
data: {
event_name: !eventName ? null : eventName,
parameters: !parameters ? {} : parameters,
source_url: window.location.href
},
success: function( data, textStatus, jqXHR ) {
//console.log( data );
},
error: function ( jqXHR, textStatus, errorThrown ) {
//console.log( jqXHR );
}
} );
};
jQuery( window ).on( ‘load’, function() {
if ( !window.bgmpGdpr || window.bgmpGdpr.isOptedOut() ) {
return;
}
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq( ‘init’, ‘436331036555416’ );
fbq( ‘track’, ‘PageView’ );
if ( ‘object’ === typeof mc4wp && mc4wp.forms ) {
mc4wp.forms.on( ‘subscribed’, function() {
// Successful MC4WP newsletter signup AJAX form submission.
window.statGlobal.analytics.fbq( ‘Lead’ );
} );
}
window.statGlobal.analytics.fbq( ‘ViewContent’ );
} );
